The Latest SPAC News and Rumors: November 1, 2021
by Marlena Haddad on 2021-11-01 at 11:28am

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Prison phone company Securus in talks to merge with Atlantic Avenue, Redbox signs content deal with Fremantle, and Singapore’s Novo Tellus files for blank-check IPO


Prison Phone Company Securus Is in SPAC Merger Talks

Tom Gores’s Platinum Equity is exploring strategic options for one of its most controversial investments, prison phone operator Securus Technologies Inc., and is in talks to take it public through a merger with a blank-check company, according to Bloomberg.

Atlantic Avenue Acquisition Corp. (NYSE:ASAQ), formed by middle-market lender MC Credit Partners, has approached Platinum about a potential deal to merge with Securus.

READ

Redbox Signs Content Deal With Fremantle to Further Rapid Expansion of Free Streaming Service

Redbox (NASDAQ:RDBX), a leading entertainment company, today announced it has signed a content deal with Fremantle to further accelerate the company’s free streaming service. The deal adds Free Ad Supported Television (FAST) channels which will make their debut on December 1. They include BUZZR, The Price Is Right: The Barker Era and the Baywatch channel.

Seaport Global Acquisition Corp. secured shareholder approval of its combination with home entertainment provider Redbox in a special meeting on October 21.

READ


Singapore’s Novo Tellus Files for Blank-Check IPO

Singapore buyout firm Novo Tellus Capital Partners has applied to list a SPAC with the city-state’s exchange, according to Bloomberg.

The technology and industrials-focused firm is planning to raise between S$200 million ($148 million) and S$250 million through an IPO of the blank-check company. The IPO could take place as soon as the end of this year.

READ


Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID

Revelation Biosciences Inc., a clinical-stage life sciences company that is focused on the development of immunologic based therapies and diagnostics for the prevention and treatment of disease, announced today that it has engaged MedWorld Advisors to optimize the value of Revelation’s diagnostic tool, REVID™.

Revelation recently announced that it has entered into a definitive merger agreement with Petra Acquisition, Inc. (NASDAQ:PAIC) for a business combination that will result in Revelation becoming a publicly traded company. The merger is expected to close in Q4 2021.

READ

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved